共 207 条
[1]
Ajani JA(2010)Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial J Clin Oncol 28 1547-1553
[2]
Rodriguez W(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[3]
Bodoky G(2008)Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J Clin Oncol 26 1987-1992
[4]
Moiseyenko V(2007)Progression-free survival is a surrogate for survival in advanced colorectal cancer J Clin Oncol 25 5218-5224
[5]
Lichinitser M(2008)Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 99 1402-1407
[6]
Gorbunova V(2004)Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer. Pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395-2403
[7]
Vynnychenko I(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-46
[8]
Garin A(1979)Bootstrap methods: another look at the jackknife Ann Stat 7 1-26
[9]
Lang I(2010)Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer J Cancer Res Clin Oncol 136 1059-1064
[10]
Falcon S(2009)Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer J Thorac Oncol 4 311-317